Testing a blood test to predict treatment response in advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study looks at a special blood test (miRNA panel) to see if it can help predict how well treatment works for people with advanced pancreatic cancer. If you are starting FOLFIRINOX for the first time, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic pancreatic cancer (cancer that has spread to other organs).
- You are about to start your first treatment with the chemotherapy combination FOLFIRINOX.
- You are 18 years old or older.
- You have not had any chemotherapy before (like neoadjuvant or adjuvant treatment).
- You are healthy enough to receive FOLFIRINOX (for example, no severe jaundice or major weakness).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at MRI scans, computer-extracted imaging features, and blood/“liquid biopsy” tests after FOLFIRINOX chemotherapy to predict whether surgery can fully remove pancreatic cancer. It may help your care team choose the best next step—whether surgery is likely to be possible and how to plan it.
This trial studies metastatic pancreatic cancer by taking a small tissue sample and analyzing its genes. It may help doctors better understand which cancer subtypes patients have, which can guide future treatment choices.
This trial tests a combination of chemotherapy (mFOLFIRINOX) and radiation therapy for people with advanced pancreatic cancer that has stopped responding to chemotherapy and whose CA19-9 tumor marker levels are normal. The goal is to see if this approach can help when standard treatments are no longer working.
This Phase 2 study looks at different types (subtypes) of pancreatic tumors in people treated with FOLFIRINOX, a chemotherapy. It requires tumor biopsies before and after treatment to see how the tumor changes, which may help doctors better match treatments in the future.
This trial tests whether a blood test that detects tumor DNA can help doctors decide early if the standard chemotherapy is working, and if switching treatment might be better. It is for people newly diagnosed with metastatic pancreatic cancer who are starting their first chemotherapy.
This trial tests a stronger version of FOLFIRINOX chemotherapy for people with pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body. It aims to see if the new dosing schedule works better and is safe.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.